USA - NIH: Clinical trial to test immune modulation strategy for hospitalized covid-19 patients begins, Sept 2023

(mods, if there's a more applicable spot to share, feel free to move to)

https://www.nih.gov/news-events/new...trategy-hospitalized-covid-19-patients-begins

9/22/23, NIH: "Clinical trial to test immune modulation strategy for hospitalized covid-19 patients begins"

"Part of NIH’s STRIVE Consortium (Strategies and Treatments for Respiratory Infections and Viral Emergencies), the therapeutic may prevent overactive immune systems from causing severe symptoms."

‘The drug being used to test the strategy of early intensification of immune modulation, abatacept (or Orencia), is manufactured by Bristol Myers Squibb, Princeton, New Jersey. Researchers think it may also be useful as an immune modulator for COVID-19 by tamping down over-active immune responses.’

"Abatacept works by binding to and blocking molecules that normally activate T cells, a key part of the immune system. Other immune cells may also be affected by the drug. For patients taking abatacept, the immune system may be less likely to “overreact” when fighting an infection such as COVID-19.."

'It is supported by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) in partnership with NIH’s National Center for Advancing Translational Sciences (NCATS).'